Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 21, 2024 07:00 ET
|
Cabaletta Bio
– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™...
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
March 20, 2024 07:00 ET
|
Cabaletta Bio
PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
February 27, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
February 01, 2024 16:30 ET
|
Cabaletta Bio
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
January 08, 2024 07:00 ET
|
Cabaletta Bio
– Second and third FDA Fast Track Designations for CABA-201, following the systemic lupus erythematosus (SLE) and lupus nephritis (LN) designation, providing the opportunity for expedited development...
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 28, 2023 16:30 ET
|
Cabaletta Bio
PHILADELPHIA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023 07:00 ET
|
Cabaletta Bio
– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clinical site actively recruiting patients...
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
November 06, 2023 07:00 ET
|
Cabaletta Bio
– First cleared CD19-CAR T IND application for generalized myasthenia gravis announced in the U.S. and fourth IND clearance for CABA-201 across a broad range of autoimmune diseases – – Clearance...